Akhtar Ashfaq - Opko Health President
| OPK Stock | 458.50 13.50 2.86% |
President
Dr. Akhtar Ashfaq, M.D. serves as Senior Vice President Clinical Research and Development of Renal Division of the Company. He supports the ongoing adoption of RAYALDEE extendedrelease capsules by healthcare professionals who care for patients with stage 3 or 4 chronic kidney disease . He will lead the further development of RAYALDEE for the treatment of secondary hyperparathyroidism in adults with stage 5 CKD and vitamin D insufficiency who require regular hemodialysis. He also will lead the development of ALPHAREN tablets for the treatment of hyperphosphatemia in adults with stage 5 CKD since 2017.
| Tenure | 7 years |
| Professional Marks | Ph.D |
| Phone | 305 575 4100 |
| Web | https://www.opko.com |
Opko Health Management Efficiency
The company has return on total asset (ROA) of (0.0659) % which means that it has lost $0.0659 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.1867) %, meaning that it generated substantial loss on money invested by shareholders. Opko Health's management efficiency ratios could be used to measure how well Opko Health manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Dalia Gonen | Elbit Systems | 62 | |
| Elad Aharonson | Elbit Systems | 45 | |
| Richard Daniell | Teva Pharmaceutical Industries | 52 | |
| Gideon Sheffer | Elbit Systems | 68 | |
| Yehuda Vered | Elbit Systems | 65 | |
| Gary Saunders | Tower Semiconductor | 54 | |
| Sigal Feferman | Nice | 46 | |
| Yoram Shmuely | Elbit Systems | 62 | |
| Eric Drape | Teva Pharmaceutical Industries | 61 | |
| Adi Dar | Elbit Systems | 44 | |
| David Temin | Elbit Systems | 67 | |
| Eli Kalif | Teva Pharmaceutical Industries | N/A | |
| Shani Dotan | Kamada | 41 | |
| Darren Rushworth | Nice | N/A | |
| Yehoshua Yehuda | Elbit Systems | 55 | |
| Kevin Mannix | Teva Pharmaceutical Industries | N/A | |
| Eitan Kyiet | Kamada | N/A | |
| John OHara | Nice | 65 | |
| Jonathan Ariel | Elbit Systems | 62 | |
| Brendan OGrady | Teva Pharmaceutical Industries | 52 | |
| Miki Migdal | Nice | 56 | |
Management Performance
| Return On Equity | -0.19 | |||
| Return On Asset | -0.0659 |
Opko Health Leadership Team
Elected by the shareholders, the Opko Health's board of directors comprises two types of representatives: Opko Health inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Opko. The board's role is to monitor Opko Health's management team and ensure that shareholders' interests are well served. Opko Health's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Opko Health's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Arie Gutman, Pres API | ||
| Richard Lerner, Independent Director | ||
| Dmitry Kolosov, Independent Director | ||
| Thomas Nusbickel, Chief Commercial Officer of the Company's Renal Division | ||
| Elias MD, Pres Chairman | ||
| Richard Pfenniger, Independent Director | ||
| Philip Frost, Chairman of the Board, CEO | ||
| Thomas Beier, Director | ||
| Akhtar Ashfaq, Senior Vice President - Clinical Research and Development of OPKO Health's Renal Division | ||
| Jon Cohen, Executive Chairman of BioReference Laboratories | ||
| Robert Fishel, Independent Director | ||
| Robert Baron, Independent Director | ||
| Anne Fields, IR Contact Officer | ||
| Adam Logal, CFO, Chief Accounting Officer, Sr. VP and Treasurer | ||
| Alice Yu, Independent Director | ||
| Steven Rubin, Executive Vice President - Administration, Director | ||
| JD Esq, Chief Laboratories | ||
| James DeMarco, VP Sales | ||
| John Paganelli, Independent Director | ||
| Phillip Frost, Chairman of the Board, CEO | ||
| Miriam Miller, IR Contact Officer | ||
| MBA MBA, Vice Officer | ||
| Jon MD, Advisor | ||
| Jane Hsiao, Vice Chairman of the Board, Chief Technical Officer | ||
| Geoff Monk, President of BioReference | ||
| Richard Krasno, Independent Director |
Opko Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Opko Health a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.19 | |||
| Return On Asset | -0.0659 | |||
| Profit Margin | (0.26) % | |||
| Operating Margin | (0.20) % | |||
| Current Valuation | 3.9 B | |||
| Shares Outstanding | 772.69 M | |||
| Shares Owned By Insiders | 45.87 % | |||
| Shares Owned By Institutions | 24.36 % | |||
| Price To Book | 0.63 X | |||
| Price To Sales | 2.78 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Opko Health. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Opko Stock refer to our How to Trade Opko Stock guide.You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Complementary Tools for Opko Stock analysis
When running Opko Health's price analysis, check to measure Opko Health's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Opko Health is operating at the current time. Most of Opko Health's value examination focuses on studying past and present price action to predict the probability of Opko Health's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Opko Health's price. Additionally, you may evaluate how the addition of Opko Health to your portfolios can decrease your overall portfolio volatility.
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |